Newland Labs & Navin Fluorine: Which Stock Offers Better Long-Term Returns?

Newland Laboratories delivered another strong quarterly performance, sending the stock sharply higher after earnings. Vinit Bolinjkar, Head Research, Ventura Securities, believes the company remains one of the strongest stories in the pharma space, driven by its leadership in peptides and complex chemistries. He highlights consistent volume growth, expanding margins, and improving profitability as key strengths supporting the long-term outlook. In this Business Today interview, Vinit Bolinjkar explains why he remains bullish on Newland Labs, discusses its growth prospects, and shares whether investors should continue buying the stock even after its recent rally.